Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Last trade$6.11
Day change-$0.18 (-2.86%)
Day range$5.98 – $6.51
Volume621,487
Market cap$285M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$284.6M
Price / earnings
9.66×
Price / book
-2.7×
Price / sales
2.12×
EV / sales
1.85×
EV / EBITDA
4.55×
Profitability
Earnings per share
$0.65
Return on assets
12%
Return on equity
-27.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.28×
Current ratio
0.73×
Quick ratio
0.73×
Cash ratio
0.33×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$103.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AGEN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$31.49M
$34.52M
$33.74M
$34.2M
$30.24M
$25.69M
$24.07M
$26.84M
Cost of revenue
$0
$0
$0
$0
$642K
$243K
$137K
$118K
Gross profit
$31.49M
$34.52M
$33.74M
$34.2M
$29.59M
$25.45M
$23.93M
$26.72M
Selling, general and administrative
$8.43M
$8.47M
$6.86M
$12.3M
$10.86M
$15.52M
$15.72M
$20.93M
Research and development
$11.65M
$14.76M
$11.82M
$7.51M
$23.6M
$26.71M
$21.52M
$33.78M
Total operating expenses
$20.08M
$23.23M
$18.68M
$19.81M
$34.14M
$42.16M
$37.24M
$52.62M
Operating income
$11.41M
$11.29M
$15.05M
$14.4M
-$4.55M
-$16.71M
-$13.31M
-$25.9M
Interest expense
-$14.52M
-$15.24M
$0
$0
-$13.17M
-$13.29M
$0
$0
Income before taxes
$2.73M
-$567K
$39.21M
-$10.61M
$63.91M
-$30.01M
-$26.37M
-$46.81M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$2.73M
-$567K
$39.21M
-$10.61M
$63.91M
-$30.01M
-$26.37M
-$46.81M
Net income attributable to common shareholders
$1.52M
-$604K
$39.17M
-$10.63M
$63.86M
-$28.01M
-$25.32M
-$45.91M
EBITDA
$11.92M
$11.81M
$15.64M
$15M
-$1.51M
-$13.54M
-$10.11M
-$22.64M
Basic earnings per share
$0.02
-$0.01
$1.03
-$0.31
$2.00
-$1.00
-$1.03
-$2.00
Diluted earnings per share
$0.02
-$0.01
$1.02
-$0.32
$1.94
-$1.00
-$1.03
-$2.00
Recent news
Company coverage with links to the original publishers.
Agenus (AGEN) reported Q3 2026 earnings of 2 cents per share matching estimates, but revenues of $31.5 million missed consensus expectations of $35 million. Pre-commercial BOT+BAL product revenues declined 6.3% sequentially while non-cash royalties fell 12.4% year-over-year. The stock fell 7.6% following the results. The company received its first-ever drug approvals in Armenia and plans to launch the phase III ROBBIN study in Q1'27, with interim data expected in H2'27.
Agenus (AGEN) reported Q3 2026 earnings of $0.02 per share, matching consensus estimates but missing revenue expectations by 10.03% at $31.49 million. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, suggesting underperformance ahead. Despite a 122% year-to-date gain, the biotech company has only surpassed EPS estimates once in the last four quarters.
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.
A comprehensive market report reveals over 40 companies developing 50+ CTLA-4 inhibitor drugs for cancer immunotherapy. Key developments include FDA approvals for tremelimumab in hepatocellular cancer and MT-8421 for solid tumors, along with promising clinical progress from multiple biopharmaceutical companies in checkpoint inhibitor combinations and bispecific antibodies.
Agenus reported Q3 2024 results highlighting groundbreaking clinical progress with BOT/BAL immunotherapy in hard-to-treat cancers, particularly microsatellite-stable colorectal cancer. However, the company faces significant financial constraints with only $44.8 million in cash at quarter-end. Management is pursuing cost reductions, real estate asset monetization ($45M+ in properties), and strategic partnerships to fund Phase 3 trials and extend runway. Multiple data presentations from neoadjuvant trials are expected in early 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.